ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Humacyte Inc

Humacyte Inc (HUMA)

2.37
-0.04
(-1.66%)
2.3798
0.0098
(0.41%)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
2.3798
Bid
2.37
Ask
2.38
Volume
2,722,400
2.29 Day's Range 2.46
1.15 52 Week Range 9.79
Market Cap
Previous Close
2.41
Open
2.30
Last Trade Time
Financial Volume
$ 6,480,594
VWAP
2.3805
Average Volume (3m)
5,066,618
Shares Outstanding
155,118,816
Dividend Yield
-
PE Ratio
-11.43
Earnings Per Share (EPS)
-0.96
Revenue
-
Net Profit
-148.7M

About Humacyte Inc

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases,... Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Show more

Sector
Blank Checks
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
2020
Humacyte Inc is listed in the Blank Checks sector of the NASDAQ with ticker HUMA. The last closing price for Humacyte was $2.41. Over the last year, Humacyte shares have traded in a share price range of $ 1.15 to $ 9.79.

Humacyte currently has 155,118,816 shares outstanding. The market capitalization of Humacyte is $373.84 million. Humacyte has a price to earnings ratio (PE ratio) of -11.43.

Humacyte (HUMA) Options Flow Summary

Overall Flow

Bearish

Net Premium

-30k

Calls / Puts

0.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

HUMA Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2802-10.53383458652.662.932.3745212632.56799486CS
40.469824.59685863871.912.931.790349874182.52445441CS
12-0.7702-24.45079365083.153.361.1550666181.9362926CS
26-1.7402-42.23786407774.126.771.1545040923.03389693CS
52-4.9002-67.31043956047.289.791.1538094274.2492137CS
156-1.6202-40.50549.971.1517218714.23068382CS
260-7.6202-76.2021017.451.1514573714.47925858CS

HUMA - Frequently Asked Questions (FAQ)

What is the current Humacyte share price?
The current share price of Humacyte is $ 2.3798
How many Humacyte shares are in issue?
Humacyte has 155,118,816 shares in issue
What is the market cap of Humacyte?
The market capitalisation of Humacyte is USD 373.84M
What is the 1 year trading range for Humacyte share price?
Humacyte has traded in the range of $ 1.15 to $ 9.79 during the past year
What is the PE ratio of Humacyte?
The price to earnings ratio of Humacyte is -11.43
What is the reporting currency for Humacyte?
Humacyte reports financial results in USD
What is the latest annual profit for Humacyte?
The latest annual profit of Humacyte is USD -148.7M
What is the registered address of Humacyte?
The registered address for Humacyte is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Humacyte website address?
The website address for Humacyte is www.humacyte.com
Which industry sector does Humacyte operate in?
Humacyte operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

HUMA Discussion

View Posts
threebabiesbusy threebabiesbusy 5 days ago
I noticed that too....Go HUMA! Fly on the wall has good article info too.
👍️0
Mr Stock pick Mr Stock pick 6 days ago
I’m here, but stocktwits board is more active
Waiting on catalyst but everyone is bullish
Great year ahead with possibilities of buyout
👍️0
threebabiesbusy threebabiesbusy 1 week ago
Is anyone around?
👍️0
roadkilll roadkilll 1 month ago
The first FDA approval lends validation to early stage trials

Nov. 18, 2024

In the preclinical study, the sdATEV was implanted between the aorta and right coronary artery (RCA) in five baboons to simulate a CABG procedure. Animals were followed for six months after sdATEV implantation and all sdATEVs maintained patency throughout the study. The baboon study provided an effective model for demonstrating the feasibility, mechanical durability and capacity for host-cell remodeling of the sdATEV for CABG.

“Our results show that the sdATEV not only supports coronary blood flow but also host recellularization and adaptive remodeling in a challenging preclinical surgical model,” said Dr. Kirkton
👍️ 1
Monksdream Monksdream 1 month ago
HUMA under $2
👍️0
Monksdream Monksdream 2 months ago
HUMA, under $2
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Bloomberg US Approved Device for Battlefield Injuries Despite Serious Risks, Former FDA Reviewer Says
https://www.bloomberg.com/news/articles/2025-03-25/us-approved-device-for-battlefield-injuries-despite-serious-risks-former-fda-reviewer-says
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
JAMA Bioengineered Human Arteries for the Repair of Vascular Injuries
https://jamanetwork.com/journals/jamasurgery/fullarticle/2826564
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
FDA Clinical Review Memo - Symvess
https://www.fda.gov/media/185229/download?attachment
👍️0
Monksdream Monksdream 2 months ago
HUMA, recent 52 week low
👍️0
threebabiesbusy threebabiesbusy 3 months ago
I’m a LT holder…..
D. Boral Capital says the selloff in shares of Humacyte (HUMA) following the company’s $50M capital raise is a buying opportunity. While the stock weakness reflects dilution concerns, the additional capital significantly strengthens Humacyte’s financial position, the analyst tells investors in a research note. With its FDA-approved cellular tissue-engineered vessels “poised to revolutionize vascular trauma,” D. Boral views the current pullback as an opportunity to accumulate shares. It keeps a Buy rating on Humacyte with a $25
👍️0
threebabiesbusy threebabiesbusy 3 months ago
D. Boral Capital says the selloff in shares of Humacyte (HUMA) following the company’s $50M capital raise is a buying opportunity. While the stock weakness reflects dilution concerns, the additional capital significantly strengthens Humacyte’s financial position, the analyst tells investors in a research note. With its FDA-approved cellular tissue-engineered vessels “poised to revolutionize vascular trauma,” D. Boral views the current pullback as an opportunity to accumulate shares. It keeps a Buy rating on Humacyte with a $25
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
Specific information based from the NYT article? That combined with the announced dilution makes for a bad shareholder's day.
👍️0
threebabiesbusy threebabiesbusy 3 months ago
Shortly after FDA approval, Humacyte began receiving requests for quotations for Symvess from hospitals. Twenty-one hospitals have already initiated the VAC approval process, with additional hospitals expected to commence the process. These hospitals are a mix of leading trauma centers that were participants in Humacyte clinical studies combined with institutions newly introduced to Symvess.
👍️0
TrendTrade2016 TrendTrade2016 3 months ago
nope
👍️0
threebabiesbusy threebabiesbusy 3 months ago
Good morning TT. Are you holding a position or trading shares?
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
HUMA READY FOR 4.00
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
HUMA RAMPING
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Commercial launch of Symvess. Feb. 26, 2025
https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-announces-commercial-launch-symvesstm-acellular-tissue
👍️0
TrendTrade2016 TrendTrade2016 4 months ago
HUMA BACK IN PLAY
👍️0
FooBarAndGrill FooBarAndGrill 4 months ago
Humacyte and Pluristyx Partnership will aim to normalize glucose levels in diabetic patients.
https://humacyte.gcs-web.com/news-releases/news-release-details/humacyte-and-pluristyx-announce-gene-editing-partnership-support
👍️ 1
FooBarAndGrill FooBarAndGrill 5 months ago
Humacyte plans to file an IND for the small-diameter (3.5mm) acellular tissue engineered vessel (sdATEV) in coronary artery bypass grafting (CABG).
https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-planned-ind-filing-2025-support-first-human
👍️0
roadkilll roadkilll 5 months ago
In the preclinical study, the sdATEV was implanted between the aorta and right coronary artery (RCA) in five baboons to simulate a CABG procedure. Animals were followed for six months after sdATEV implantation and all sdATEVs maintained patency throughout the study. The baboon study provided an effective model for demonstrating the feasibility, mechanical durability and capacity for host-cell remodeling of the sdATEV for CABG. After implantation, the sdATEV was observed to recellularize with host cells and remodel to form a multi-layered tissue including transanastomotic neomedial tissue that effectively reduced the initial size mismatch with the RCA. The neomedial tissue observed at six months was predominantly composed of quiescent contractile smooth muscle cells under a lining of functional endothelial cells.
“Our results show that the sdATEV not only supports coronary blood flow but also host recellularization and adaptive remodeling in a challenging preclinical surgical model,” said Dr. Kirkton.
.
Functional organs from the Humacyte scaffold without autoimmune complications. No idea where the valuation would be.
👍️0
Rubraquercus Rubraquercus 5 months ago
In 2010, the HUMA co-founder and CEO, Dr. Laura Niklason and her colleagues were able to successfully produce an engineered rat lung that could inhale and exhale carbon dioxide.

Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine.[3][4] Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine.

en.wikipedia.org/wiki/Laura...
👍️ 1
roadkilll roadkilll 5 months ago
Acellular Tissue Engineered Vessels - ATEV
FDA approved as safe and effective in human use

Vascular Trauma - big step in validation of ATEV and future indications

* Dialysis (AV access) - phase III study completed and proved safe and effective
* Peripheral Artery Disease - just a matter of time for approval as same technology for vascular Trauma
* Coronary Artery Bypass Grafting (CABG) - same technology works here as in vascular Trauma. Around 400,000 patients yearly.
.
This would all be low hanging fruit now that ATEV is FDA approved and are just a matter of patience. The technology has potential well beyond ATEV.
👍️0
Tiger Money Tiger Money 5 months ago
Very nice DD
👍️0
Rubraquercus Rubraquercus 5 months ago
1. Assigned Priority Review Designation by Secretary of Defense under Law 115-92 which is used for military purposes. mrdc.health.mil/index.cfm/a...

2. In the latest Humacyte slide deck it says "Humacyte expects DOD to stockpile for deployment to sites of conflicts.

3. The Phase 2/3 clinical data included wartime injuries in both Ukraine, and Israel the two largest warzones right now.

4. In this article from 10/16/24 CEO Laura says the Department of Defense "Sponsored some of their trials". ncchamber.com/2024/10/16/du...

5. Received RMAT designation only given to products with an "unmet need" in the field fda.gov/vaccines-blood-biol....

6. The DOD gave them $1,000,000 Grant in 2017 Through the Medical Technology Enterprise Consortium (MTEC).

7. The DOD gave them $3,400,000 Contract Award through the BAA to support the Phase 2 studies. biospace.com/humacyte-award...
👍️ 2
Rubraquercus Rubraquercus 5 months ago
In 2010, the HUMA co-founder and CEO, Dr. Laura Niklason and her colleagues were able to successfully produce an engineered rat lung that could inhale and exhale carbon dioxide.

Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine.[3][4] Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine.

en.wikipedia.org/wiki/Laura...
👍️ 1
threebabiesbusy threebabiesbusy 6 months ago
Humacyte price target raised to $17 from $15 at Benchmark. Looking forward to 2025. Insider buying and pt upgrades bode well for positive moves going forward.
GLTA
3
👍 1
sblzng sblzng 6 months ago
It's gonna go .Interest is picking up and more buys than sells
👍️0
Monksdream Monksdream 6 months ago
HUMA under $5

[color=red][/color]
👍️0
threebabiesbusy threebabiesbusy 6 months ago
Wainwright analyst Vernon Bernardino raised the firm's price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb ...
👍️0
threebabiesbusy threebabiesbusy 6 months ago
Let's push through the $4.80 wall!
👍️0
threebabiesbusy threebabiesbusy 6 months ago
awww so you're out. Looks difficult for afternoon move up
👍️0
threebabiesbusy threebabiesbusy 6 months ago
We're trading substantially below days VWAP....
👍️0
threebabiesbusy threebabiesbusy 6 months ago
Lunch time pull back. Do you anticipate afternoon trend back up? Or do we call it one and done!
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
EXITED ON THAT PUSH BOTTOM BOUNCE
👍️0
Tiger Money Tiger Money 6 months ago
Love having you back.  You are one of the smartest traders out there.  Unfortunately you like to be mean to less intelligent people 😝.  Anyways, how far do you think this could run?  Thanks
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Now, reality bites.
Cash and time to ramp up.
Will vascular surgeons switch from the old and familiar?
TBD.
👍️0
TrendTrade2016 TrendTrade2016 6 months ago
HUMA READY TO RUN AGAIN
👍️0
Tiger Money Tiger Money 6 months ago
Finally!
👍️ 1
FooBarAndGrill FooBarAndGrill 6 months ago
Approved
https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue
👍️ 1
FooBarAndGrill FooBarAndGrill 6 months ago
Today is Dec 9th. Dec 9th marks 10 months since HUMA's PDUFA application.
FDA has performance goals. For regular PDUFA applications the goal is 90% within 10 months.
FDA performance goals: https://www.fda.gov/media/151712/download
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
I don't know of any. But you can roll your own using eg. Amazon Transcribe.
👍️0
tm100 tm100 6 months ago
Is there a transcript available anywhere? Have not had any success finding a transcript
👍️0
Tiger Money Tiger Money 6 months ago
Good news that they don't pull the plug.  This will be accepted by RFK less than a month in office 
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
The FDA is the wall. She can't say anything.
Adding that FDA has performance goals which, in this case, are not being met.
👍️0
Tiger Money Tiger Money 6 months ago
You say ok.  So everything is moving forward with the fda still?  Thanks 
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Webcast OK. Direct questions and direct answers.
👍️0
FooBarAndGrill FooBarAndGrill 6 months ago
Supplemental BLA. Discussed during webcast.
Replay is up. https://investors.humacyte.com/news-events/events-and-presentations
👍️0

Your Recent History

Delayed Upgrade Clock